ATAI THERAPEUTICS Trademark

Trademark Overview

On Monday, September 25, 2023, a trademark application was filed for ATAI THERAPEUTICS with the United States Patent and Trademark Office. The USPTO has given the ATAI THERAPEUTICS trademark a serial number of 98195493. The federal status of this trademark filing is THIRD EXTENSION - GRANTED as of Tuesday, April 7, 2026. This trademark is owned by Atai Therapeutics, Inc.. The ATAI THERAPEUTICS trademark is filed in the Insurance & Financial Services category with the following description:

Financial and monetary services, namely, financial consultation and capital investor services with regard to clinical development of compounds and operational setup of biotechnology companies; banking; fiscal valuation services; capital market fundraising and financial sponsorship of biotechnology companies and clinical studies; pawn brokerage
atai therapeutics

General Information

Serial Number98195493
Word MarkATAI THERAPEUTICS
Filing DateMonday, September 25, 2023
Status732 - THIRD EXTENSION - GRANTED
Status DateTuesday, April 7, 2026
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, August 13, 2024

Trademark Statements

Goods and ServicesFinancial and monetary services, namely, financial consultation and capital investor services with regard to clinical development of compounds and operational setup of biotechnology companies; banking; fiscal valuation services; capital market fundraising and financial sponsorship of biotechnology companies and clinical studies; pawn brokerage
NOT AVAILABLETHERAPEUTICS

Classification Information

International Class036 - Insurance; financial affairs; monetary affairs; real estate affairs.
US Class Codes100, 101, 102
Class Status Code6 - Active
Class Status DateWednesday, October 11, 2023
Primary Code036
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History

Party NameAtai Therapeutics, Inc.
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressNew York, NY 10119
US
Party NameAtai Therapeutics, Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressEncinitas, CA 92024
US

Trademark Events

Event DateEvent Description
Thursday, September 28, 2023NEW APPLICATION ENTERED
Wednesday, October 11, 2023NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Thursday, May 16, 2024ASSIGNED TO EXAMINER
Wednesday, May 22, 2024NON-FINAL ACTION WRITTEN
Wednesday, May 22, 2024NON-FINAL ACTION E-MAILED
Wednesday, May 22, 2024NOTIFICATION OF NON-FINAL ACTION E-MAILED
Tuesday, July 2, 2024TEAS RESPONSE TO OFFICE ACTION RECEIVED
Tuesday, July 2, 2024CORRESPONDENCE RECEIVED IN LAW OFFICE
Tuesday, July 2, 2024TEAS/EMAIL CORRESPONDENCE ENTERED
Wednesday, July 3, 2024APPROVED FOR PUB - PRINCIPAL REGISTER
Wednesday, July 24, 2024NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Tuesday, August 13, 2024PUBLISHED FOR OPPOSITION
Tuesday, August 13, 2024OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, October 8, 2024NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Tuesday, February 18, 2025SOU TEAS EXTENSION RECEIVED
Tuesday, February 18, 2025SOU EXTENSION 1 FILED
Tuesday, February 18, 2025SOU EXTENSION 1 GRANTED
Wednesday, February 19, 2025NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Tuesday, September 23, 2025SOU TEAS EXTENSION RECEIVED
Tuesday, September 23, 2025SOU EXTENSION 2 FILED
Tuesday, September 23, 2025SOU EXTENSION 2 GRANTED
Tuesday, September 23, 2025NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Thursday, April 2, 2026TEAS CHANGE OF OWNER ADDRESS RECEIVED
Thursday, April 2, 2026APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Thursday, April 2, 2026TEAS CHANGE OF CORRESPONDENCE RECEIVED
Tuesday, April 7, 2026SOU TEAS EXTENSION RECEIVED
Tuesday, April 7, 2026SOU EXTENSION 3 FILED
Tuesday, April 7, 2026SOU EXTENSION 3 GRANTED
Wednesday, April 8, 2026NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED

Related Keywords

therapeutics atai services financial capital clinical biotechnology companies valuation fiscal market fundraising